These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31999669)

  • 21. In brief: A new prostate cancer indication for darolutamide (Nubeqa).
    Med Lett Drugs Ther; 2023 Jun; 65(1679):e108. PubMed ID: 37339095
    [No Abstract]   [Full Text] [Related]  

  • 22. Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.
    Matsubara N; Mukai H; Hosono A; Onomura M; Sasaki M; Yajima Y; Hashizume K; Yasuda M; Uemura M; Zurth C
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1063-1072. PubMed ID: 28801852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.
    Shore ND; Gratzke C; Feyerabend S; Werbrouck P; Carles J; Vjaters E; Tammela TLJ; Morris D; Aragon-Ching JB; Concepcion RS; Emmenegger U; Fleshner N; Grabbert M; Lietuvietis V; Mahammedi H; Cruz FM; Paula A; Pieczonka C; Rannikko A; Richardet M; Silveira G; Kuss I; Le Berre MA; Verholen F; Sarapohja T; Smith MR; Fizazi K
    Oncologist; 2024 Jul; 29(7):581-588. PubMed ID: 38394384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cases in the management of nonmetastatic castration-resistant prostate cancer: darolutamide as the first androgen receptor inhibitor in a fit, older man.
    Lowentritt BH
    Clin Adv Hematol Oncol; 2022 Jan; 20 Suppl 1(1):1-8. PubMed ID: 35343943
    [No Abstract]   [Full Text] [Related]  

  • 25. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
    Smith MR; Hussain M; Saad F; Fizazi K; Sternberg CN; Crawford ED; Kopyltsov E; Park CH; Alekseev B; Montesa-Pino Á; Ye D; Parnis F; Cruz F; Tammela TLJ; Suzuki H; Utriainen T; Fu C; Uemura M; Méndez-Vidal MJ; Maughan BL; Joensuu H; Thiele S; Li R; Kuss I; Tombal B;
    N Engl J Med; 2022 Mar; 386(12):1132-1142. PubMed ID: 35179323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.
    Kumar J; Jazayeri SB; Gautam S; Norez D; Alam MU; Tanneru K; Bazargani S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
    Urol Oncol; 2020 Nov; 38(11):826-834. PubMed ID: 32605736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug-drug interactions.
    Conde-Estévez D; Henríquez I; Muñoz-Rodríguez J; Rodriguez-Vida A
    Expert Opin Drug Metab Toxicol; 2022 Sep; 18(9):601-613. PubMed ID: 36111393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prostate cancer - enzalutamide extends survival].
    Aktuelle Urol; 2014 Mar; 45(2):98. PubMed ID: 24818263
    [No Abstract]   [Full Text] [Related]  

  • 29. Darolutamide for non-metastatic castration-resistant prostate cancer: Efficacy, safety, and clinical perspectives of use.
    Yang CK; Cha TL; Chang YH; Huang SP; Lin JT; Wang SS; Huang CY; Pang ST
    J Formos Med Assoc; 2023 Apr; 122(4):299-308. PubMed ID: 36797129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apalutamide: A Review in Metastatic Castration-Sensitive Prostate Cancer.
    Hoy SM
    Drugs; 2020 Oct; 80(15):1579-1585. PubMed ID: 32930958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Based on ARASENS trial: efficacy and safety of darolutamide as an emerging option of endocrinotherapy for metastatic hormone-sensitive prostate cancer-an updated systematic review and network meta-analysis.
    Dou M; Liang H; Liu Y; Zhang Q; Li R; Chen S; Shi B
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7017-7027. PubMed ID: 36856851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety differences across androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer.
    Shore N; Garcia-Horton V; Terasawa E; Ayyagari R; Grossman JP; Waldeck AR
    Future Oncol; 2023 Feb; 19(5):385-395. PubMed ID: 36794575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover Trial.
    Williams SCR; Mazibuko N; O'Daly O; Zurth C; Patrick F; Kappeler C; Kuss I; Cole PE
    Target Oncol; 2023 May; 18(3):403-413. PubMed ID: 37103658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Galeterone activity in castration-resistant prostate cancer.
    Yaqub F
    Lancet Oncol; 2015 Jan; 16(1):e10. PubMed ID: 25638544
    [No Abstract]   [Full Text] [Related]  

  • 35. Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.
    Shore N; Zurth C; Fricke R; Gieschen H; Graudenz K; Koskinen M; Ploeger B; Moss J; Prien O; Borghesi G; Petrenciuc O; Tammela TL; Kuss I; Verholen F; Smith MR; Fizazi K
    Target Oncol; 2019 Oct; 14(5):527-539. PubMed ID: 31571095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis.
    Rizzo A; Merler S; Sorgentoni G; Oderda M; Mollica V; Gadaleta-Caldarola G; Santoni M; Massari F
    Expert Opin Drug Metab Toxicol; 2021 Oct; 17(10):1237-1243. PubMed ID: 34407702
    [No Abstract]   [Full Text] [Related]  

  • 37. [Androgen receptor inhibitors in prostate cancer: new drugs, but for which patient?].
    Vis AN; van Moorselaar RJA
    Ned Tijdschr Geneeskd; 2019 Nov; 163():. PubMed ID: 32073798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Degradation of Androgen Receptor through Small Molecules for Prostate Cancer.
    Ge R; Xu X; Xu P; Li L; Li Z; Bian J
    Curr Cancer Drug Targets; 2018; 18(7):652-667. PubMed ID: 29110617
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apalutamide for the treatment of prostate cancer.
    Rathkopf DE; Scher HI
    Expert Rev Anticancer Ther; 2018 Sep; 18(9):823-836. PubMed ID: 30101644
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer.
    Tsuchiya T; Imanaka K; Iwaki Y; Oyama R; Hashine K; Yamaguchi A; Uemura H
    Int J Clin Oncol; 2019 Dec; 24(12):1596-1604. PubMed ID: 31446511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.